

Drug Monograph

Drug Name: **Dulera® (mometasone furoate and formoterol fumarate dihydrate) 50 mcg/5 mcg Inhalation**

Drug Class: **Inhaled Corticosteroid, Long Acting Beta Agonist**

Prepared For: MO HealthNet

Prepared By: Conduent

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.	
Dosage Forms:	Dulera is now available as a combination of mometasone furoate 50 mcg and formoterol fumarate dehydrate 5 mcg strength in a 120 metered dose inhaler.	
Manufacturer:	Manufactured for: Merck and Co., Inc., Whitehouse Station, NJ 08889.	
Indications:	Dulera is indicated for the treatment of asthma in patients 5 years of age and older. The 50 mcg/ 5 mcg dosage is indicated for children aged 5 to < 12 years of age.	
Costs:	\$311 per 120 dose inhaler. Wholesale Acquisition Cost	
Summary of Findings:	This drug is being considered for inclusion in the state specific Preferred Drug List (PDL) as non-preferred.	
Status Recommendation:	<input type="checkbox"/> Clinical Edit	<input type="checkbox"/> PA Required
	<input type="checkbox"/> Open Access	<input checked="" type="checkbox"/> PDL
Type of PA Criteria:	<input type="checkbox"/> Appropriate Indications	<input checked="" type="checkbox"/> Non-Preferred
	<input type="checkbox"/> No PA Required	<input type="checkbox"/> Preferred

Prepared by: Tyler Woods PharmD
Date: March 5, 2020